Multiple Sclerosis, Relapsing-Remitting
"Multiple Sclerosis, Relapsing-Remitting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
MeSH Number(s)
C10.114.375.500.600
C10.314.350.500.600
C20.111.258.250.500.600
Concept/Terms
Multiple Sclerosis, Relapsing-Remitting- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Relapsing Remitting
- Remitting-Relapsing Multiple Sclerosis
- Multiple Sclerosis, Remitting-Relapsing
- Remitting Relapsing Multiple Sclerosis
- Relapsing-Remitting Multiple Sclerosis
- Relapsing Remitting Multiple Sclerosis
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis, Relapsing-Remitting".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis, Relapsing-Remitting".
This graph shows the total number of publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Harvard Catalyst Profiles by year, and whether "Multiple Sclerosis, Relapsing-Remitting" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 2 | 1 | 3 |
2000 | 5 | 2 | 7 |
2001 | 4 | 0 | 4 |
2002 | 5 | 1 | 6 |
2003 | 6 | 2 | 8 |
2004 | 7 | 0 | 7 |
2005 | 6 | 2 | 8 |
2006 | 4 | 0 | 4 |
2007 | 8 | 1 | 9 |
2008 | 10 | 1 | 11 |
2009 | 11 | 2 | 13 |
2010 | 2 | 0 | 2 |
2011 | 11 | 1 | 12 |
2012 | 13 | 0 | 13 |
2013 | 8 | 3 | 11 |
2014 | 6 | 2 | 8 |
2015 | 15 | 3 | 18 |
2016 | 20 | 1 | 21 |
2017 | 8 | 0 | 8 |
2018 | 14 | 0 | 14 |
2019 | 15 | 2 | 17 |
2020 | 14 | 1 | 15 |
2021 | 14 | 1 | 15 |
2022 | 12 | 0 | 12 |
2023 | 12 | 0 | 12 |
2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
-
Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024 Mar; 83:105435.
-
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. J Med Econ. 2024 Jan-Dec; 27(1):109-125.
-
Ocrelizumab in highly disabled progressive multiple sclerosis patients. Mult Scler Relat Disord. 2024 Feb; 82:105345.
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Brain. 2023 11 02; 146(11):4633-4644.
-
Identification and management of subclinical disease activity in early multiple sclerosis: a review. J Neurol. 2024 Apr; 271(4):1497-1514.
-
Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy. Mult Scler Relat Disord. 2023 Nov; 79:105037.
-
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res. 2023 09; 12(9):e220175.
-
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurol. 2023 07 01; 80(7):739-748.
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2023 07 01; 80(7):702-713.
-
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod. J Neuroinflammation. 2023 May 30; 20(1):131.